Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPTNASDAQ:APGENASDAQ:IDRANASDAQ:IMCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$9.27+5.2%$7.82$2.99▼$10.28$1.41B1.751.59 million shs1.81 million shsAPGEApogee Therapeutics$37.81+7.3%$36.13$26.20▼$63.50$1.58B1.7521,763 shs430,847 shsIDRAIdera Pharmaceuticals$0.50$0.22▼$8.67$450.52M1.25464,030 shs21,870 shsIMCRImmunocore$29.65-0.9%$28.83$23.15▼$61.48$1.48B0.75431,101 shs525,165 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-0.06%+19.63%+14.35%+9.93%+183.12%APGEApogee Therapeutics-0.87%-10.17%+9.16%-15.32%-32.48%IDRAIdera Pharmaceuticals0.00%0.00%0.00%0.00%0.00%IMCRImmunocore+6.63%-0.60%+13.85%-0.17%-50.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADPTAdaptive Biotechnologies3.0691 of 5 stars1.42.00.04.23.82.50.6APGEApogee Therapeutics2.1151 of 5 stars3.50.00.00.02.84.20.0IDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AIMCRImmunocore3.0329 of 5 stars4.21.00.00.02.94.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.83Moderate Buy$9.836.08% UpsideAPGEApogee Therapeutics 3.00Buy$92.17143.76% UpsideIDRAIdera Pharmaceuticals 0.00N/AN/AN/AIMCRImmunocore 2.45Hold$59.1199.36% UpsideCurrent Analyst Ratings BreakdownLatest IDRA, APGE, IMCR, and ADPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025IMCRImmunocoreOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$85.00 ➝ $86.005/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$11.00 ➝ $13.005/5/2025ADPTAdaptive BiotechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.005/2/2025ADPTAdaptive BiotechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$9.00 ➝ $10.004/14/2025IMCRImmunocoreJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$54.00 ➝ $50.004/10/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.004/7/2025IMCRImmunocoreMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$38.00 ➝ $33.003/21/2025ADPTAdaptive BiotechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.00 ➝ $9.003/13/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$95.003/12/2025IMCRImmunocoreNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$71.00 ➝ $71.003/12/2025IMCRImmunocoreHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$189.53M7.43N/AN/A$1.37 per share6.77APGEApogee TherapeuticsN/AN/AN/AN/A$7.50 per shareN/AIDRAIdera PharmaceuticalsN/AN/AN/A0.29$0.56 per shareN/AIMCRImmunocore$310.20M4.79N/AN/A$7.42 per share4.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.96N/AN/AN/A-89.12%-64.65%-26.45%N/AAPGEApogee Therapeutics-$83.99M-$3.29N/AN/AN/AN/A-21.81%-20.94%5/12/2025 (Estimated)IDRAIdera Pharmaceuticals$98.09M-$0.32N/AN/AN/AN/A-68.74%-34.26%N/AIMCRImmunocore-$55.29M-$1.02N/AN/AN/A-15.87%-12.84%-5.09%N/ALatest IDRA, APGE, IMCR, and ADPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025APGEApogee Therapeutics-$1.19N/AN/AN/AN/AN/A5/7/2025Q1 2025IMCRImmunocore-$0.35$0.10+$0.45$0.10$108.82 million$125.13 million5/1/2025Q1 2025ADPTAdaptive Biotechnologies-$0.28-$0.20+$0.08-$0.20$42.13 million$52.44 million3/3/2025Q4 2024APGEApogee Therapeutics-$0.94-$1.19-$0.25-$1.19N/AN/A2/11/2025Q4 2024ADPTAdaptive Biotechnologies-$0.27-$0.23+$0.04-$0.23$46.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AAPGEApogee TherapeuticsN/AN/AN/AN/AN/AIDRAIdera PharmaceuticalsN/AN/AN/AN/AN/AIMCRImmunocoreN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.892.81APGEApogee TherapeuticsN/A16.3916.39IDRAIdera PharmaceuticalsN/A1.561.56IMCRImmunocore1.033.783.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%APGEApogee Therapeutics79.04%IDRAIdera Pharmaceuticals12.18%IMCRImmunocore84.50%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.20%APGEApogee Therapeutics36.10%IDRAIdera Pharmaceuticals5.05%IMCRImmunocore10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790151.92 million138.43 millionOptionableAPGEApogee Therapeutics9144.88 million28.77 millionOptionableIDRAIdera Pharmaceuticals3262.36 million59.21 millionOptionableIMCRImmunocore32050.07 million45.48 millionOptionableIDRA, APGE, IMCR, and ADPT HeadlinesRecent News About These CompaniesNew Strong Buy Stocks for May 8thMay 8 at 8:36 AM | zacks.comImmunocore stock rises as Q1 results top estimatesMay 7 at 1:16 PM | investing.comCompared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key MetricsMay 7 at 10:36 AM | zacks.comImmunocore reports first quarter financial results and provides a business updateMay 7 at 7:00 AM | globenewswire.comMarshall Wace LLP Reduces Holdings in Immunocore Holdings plc (NASDAQ:IMCR)May 3, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Acquires 29,832 Shares of Immunocore Holdings plc (NASDAQ:IMCR)May 1, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) & Coeptis Therapeutics (NASDAQ:COEP) Head-To-Head SurveyMay 1, 2025 | americanbankingnews.comWall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a BetApril 30, 2025 | zacks.comWells Fargo & Company MN Sells 11,120 Shares of Immunocore Holdings plc (NASDAQ:IMCR)April 28, 2025 | marketbeat.comImmunocore Holdings: A Name On My Watch ListApril 27, 2025 | seekingalpha.comRenaissance Technologies LLC Sells 179,630 Shares of Immunocore Holdings plc (NASDAQ:IMCR)April 27, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Buys 200,373 Shares of Immunocore Holdings plc (NASDAQ:IMCR)April 26, 2025 | marketbeat.comLegal & General Group Plc Acquires 20,163 Shares of Immunocore Holdings plc (NASDAQ:IMCR)April 25, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Stock Price Down 2.4% - What's Next?April 24, 2025 | marketbeat.comJump Financial LLC Has $962,000 Stake in Immunocore Holdings plc (NASDAQ:IMCR)April 24, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Stock Price Up 5% - Here's WhyApril 23, 2025 | marketbeat.comImmunocore Holdings plc (NASDAQ:IMCR) Given Average Rating of "Moderate Buy" by AnalystsApril 17, 2025 | marketbeat.comImmunocore (NASDAQ:IMCR) Given New $50.00 Price Target at JPMorgan Chase & Co.April 16, 2025 | marketbeat.comFmr LLC Sells 18,341 Shares of Immunocore Holdings plc (NASDAQ:IMCR)April 15, 2025 | marketbeat.comJ.P. Morgan Remains a Buy on Immunocore Holdings (IMCR)April 15, 2025 | markets.businessinsider.comImmunocore (NASDAQ:IMCR) Receives "Buy" Rating from Needham & Company LLCApril 12, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIDRA, APGE, IMCR, and ADPT Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$9.27 +0.46 (+5.22%) Closing price 04:00 PM EasternExtended Trading$9.38 +0.12 (+1.24%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Apogee Therapeutics NASDAQ:APGE$37.81 +2.57 (+7.29%) Closing price 04:00 PM EasternExtended Trading$37.82 +0.01 (+0.03%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Idera Pharmaceuticals NASDAQ:IDRAAceragen, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA.Immunocore NASDAQ:IMCR$29.65 -0.27 (-0.90%) Closing price 03:59 PM EasternExtended Trading$29.79 +0.14 (+0.47%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
